Trial Profile

Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 02 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ociperlimab (Primary) ; Tislelizumab (Primary) ; Capecitabine; Carboplatin; Cisplatin; Etoposide; Fluorouracil; Oxaliplatin; Paclitaxel; Pemetrexed
Indications Adenocarcinoma; Adenoid cystic carcinoma; Carcinoma; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use
Acronyms AdvanTIG-105
Sponsors BeiGene

05 Sep 2024 Status changed from active, no longer recruiting to completed.
28 Feb 2024 Planned End Date changed from 1 Oct 2024 to 1 Aug 2024.
28 Feb 2024 Planned primary completion date changed from 1 May 2024 to 1 Aug 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com